You have no items in your cart.
Pivotal Trial Begins for AMO-02 in Steinert Disease
COVID-19 News, Muscular Dystrophy News
AMO Pharma has announced the initiation of REACH-CDM, a pivotal Phase 2/3 clinical trial that will assess the efficacy and safety of the investigational medication AMO-02 (tideglusib) in children and adolescents ... Read more